HDM2024 for people with advanced solid tumors

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Anti-tumor Efficacy of HDM2024 in Participants With Advanced Solid Tumors

This trial will test HDM2024 to see if it's safe and can shrink tumors in adults with advanced solid cancers who have progressed after or cannot tolerate standard treatments.

Quick facts

• Phase: PHASE1
• Study type: Interventional
• Enrollment: 63 (estimated)
• Ages: 18 Years to 75 Years
• Sex: All
• Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (industry)
• Locations: 1 site (Shanghai, Shanghai Municipality)
• Trial ID: NCT07539285 on ClinicalTrials.gov

What this trial studies

This Phase 1, open-label study gives HDM2024 every three weeks to adults with locally advanced or metastatic solid tumors that have progressed on or are intolerant of standard therapy. Patients must have measurable disease and provide fresh or archival tumor tissue for central biomarker testing, including EGFR and HER3 by immunohistochemistry. Safety and tolerability will be monitored closely, and imaging-based tumor assessments will be performed every six weeks to look for antitumor activity. The trial is sponsored by Hangzhou Zhongmei Huadong Pharmaceutical and conducted at Shanghai East Hospital.

Who should consider this trial

Good fit: Adults 18–75 with histologically or cytologically confirmed locally advanced unresectable or metastatic solid tumors, ECOG 0–1, at least one measurable lesion, life expectancy ≥3 months, and able to provide tumor tissue for EGFR/HER3 testing who have progressed on or cannot tolerate standard treatments.

Not a fit: Patients with poor performance status (ECOG ≥2), significant organ dysfunction, no measurable disease, or tumors unlikely to express EGFR/HER3 are unlikely to benefit from participation.

Why it matters

Potential benefit: If successful, HDM2024 could provide a new treatment option that shrinks tumors for some patients whose cancers no longer respond to standard therapies.

How similar studies have performed: Antibody-drug conjugates targeting EGFR or HER3 have shown activity in some cancer types, but HDM2024 is a novel agent and its effectiveness in humans remains unproven in early-phase testing.

Eligibility criteria

Inclusion Criteria:

* 1\. Participants who voluntarily participate in this study and sign the written Informed Consent Form (ICF) after being fully informed.
* 2\. Male or female participants aged 18 to 75 years (inclusive).
* 3\. Participants with histologically or cytologically confirmed locally advanced unresectable or metastatic solid tumors who have experienced disease progression on or after standard therapy , or are intolerant to standard therapy, or for whom no effective standard of care is available.
* 4\. Participants who are able to provide fresh or archival tumor tissue during the screening period. Tumor tissue will be collected for biomarker testing at a central laboratory, including immunohistochemistry for EGFR and HER3 .
* 5\. Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1 .
* 6\. Life expectancy ≥3 months.
* 7\. According to RECIST v1.1, the participant must have at least one measurable lesion .
* 8\. Participants with good organ function as demonstrated by screening laboratory test results.
* 9\. The fertile participants agreed to take effective contraceptive measures during the study and after its conclusion; and must have a negative serum human chorionic gonadotropin (HCG) test within 7 days before dosing.
* 10\. Participants should be willing and able to complete regular visits, treatment plans, laboratory tests, and other study procedures.

Exclusion Criteria:

* 1\. Participants who have previously received ADC containing exatecan , or an ADC primarily directed against EGFR and/or HER3.
* 2\. Participants who have received the following treatments:

  1. Participants who have undergone major surgery within 4 weeks before the first dose;
  2. Participants who have received radiotherapy involving the bone marrow or extensive radiotherapy within 4 weeks before the first dose; or local radiotherapy within 2 weeks before the first dose;
  3. Participants who are receiving continuous systemic corticosteroid therapy ; low-dose corticosteroids are permitted if the dose of systemic corticosteroids has been stable for 4 weeks;
  4. Participants who have received anti-tumor treatments within 4 weeks before the first dose, or are still within 5 half-lives of the last dose of the most recent anticancer therapy (whichever is longer). Traditional Chinese medicines with approved anticancer indications within 2 weeks prior to the first administration of study drug.
* 3\. Participants with other malignant tumor within the past 5 years, other than the tumor treated in this study, with the exception of locally cured tumors .
* 4\. Participants with related AEs (except for alopecia and ≤ Grade 2 sensory neuropathy) caused by previous treatment that have not recovered to ≤ Grade 1 or baseline level.
* 5\. Participants with known weight loss of \>10% within 2 months before the first dose of the study drug or other indicators showing severe malnutrition.
* 6\. Participants with serious complications or medical histories involving important organs.
* 7\. Participants with known active central nervous system (CNS) metastasis.
* 8\. Participants with any of the cardiovascular/cerebrovascular disorders, symptoms, or manifestations.
* 9\. Participants with the following conditions will be excluded at screening: active syphilis, history of human immunodeficiency virus (HIV) infection, active hepatitis B virus (HBV) or active hepatitis C virus (HCV), with the exception of asymptomatic chronic hepatitis B or C virus carriers.
* 10\. Participants with a history of interstitial pneumonia or other moderate to severe lung disorders that seriously affect lung function.
* 11\. Participants with severe infection during the screening period.
* 12\. Participants with other diseases that may affect the efficacy and safety of the study drug.
* 13\. Participants with uncontrolled pericardial effusion, uncontrolled pleural effusion, or clinically significant moderate or greater ascites during the screening period.
* 14\. Participants with unstable thrombotic events requiring therapeutic intervention within 6 months before screening; however, thrombosis related to infusion devices is not included.
* 15\. Participants who have received a live vaccine within 30 days before the first dose, or plan to receive a live vaccine during the study period.
* 16\. Participants who have received strong CYP3A4 inhibitors and inducers therapy within 1 week before dosing, or are expected to require long-term use of strong CYP3A4 inhibitors and inducers during the study intervention and within 30 days after the last dose .
* 17\. Participants with history of solid organ transplant.
* 18\. Participants with known or suspected history of severe allergy to any component of the study drug or its analogues.
* 19\. Pregnant and lactating women.
* 20\. Participants who are deemed unsuitable for this study (e.g., poor compliance, etc.) by the investigator.

Where this trial is running

Shanghai, Shanghai Municipality

• Shanghai East Hospital — Shanghai, Shanghai Municipality, China (RECRUITING)

Study contacts

• Study coordinator: Zhou Caicun

Conditions: Advanced Solid Tumors, ADC, advanced solid tumors, EGFR, HER3